RARE DISEASE
Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form
Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form
Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form
Synonyms: Autosomal recessive dystrophic epidermolysis bullosa generalisata gravis, Autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type, Generalized RDEB, severe form, RDEB generalisata gravis, RDEB, Hallopeau-Siemens type, Severe generalized RDEB
Synonyms: Autosomal recessive dystrophic epidermolysis bullosa generalisata gravis, Autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type, Generalized RDEB, severe form, RDEB generalisata gravis, RDEB, Hallopeau-Siemens type, Severe generalized RDEB
Synonyms: Autosomal recessive dystrophic epidermolysis bullosa generalisata gravis, Autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type, Generalized RDEB, severe form, RDEB generalisata gravis, RDEB, Hallopeau-Siemens type, Severe generalized RDEB
Drug discovery
1
drug
With orphan designation
Overview
Autosomal recessive generalized dystrophic epidermolysis bullosa (RDEB), severe form, is a genetic blistering disorder caused by biallelic COL7A1 mutations, resulting in deficient type VII collagen and impaired dermal-epidermal adhesion. Neonates present with widespread skin/mucosal blistering, progressing to scarring, digit fusion, and extracutaneous complications (esophageal strictures, malnutrition, corneal scarring). Lifelong risks include aggressive squamous cell carcinoma (90% cumulative risk by age 55) and chronic renal failure [1][3][9]. Diagnosis combines immunofluorescence mapping, electron microscopy, and genetic testing [1][4].
Burden
Morbidity/Mortality: Median life expectancy <35 years due to metastatic SCC (80% mortality rate by age 55) [1][5]. Chronic anemia, growth retardation, and organ dysfunction prevalent [7][16].
Economic impact: Annual direct costs >€100,000 in severe cases; ~40% of costs attributed to dressings [11][18].
Quality of life: Severe pruritus/pain (comparable to chronic urticaria), ≥17h/week spent on wound care, and caregiver dependency [7][11][17].
Therapies
Supportive care: Protective wound dressings, infection control, nutritional support (e.g., gastrostomy), and surgical interventions for strictures/hand deformities [1][17].
Emerging therapies: Topical gene therapy (beremagene geperpavec/B-VEC), ex vivo COL7A1-corrected keratinocyte grafts (EB-101), and intradermal allogeneic fibroblast injections [6][10][14].
Symptom management: Multidisciplinary pain control, vitamin/mineral supplementation, and SCC surveillance [1][7].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare skin diseases
Research Papers
217 drug discovery papers about Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form, with 5 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
217 drug discovery papers about Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form, with 5 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-11 | Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy - a case series.
Recessive dystrophic epidermolysis bullosa is a severe inherited blistering disorder characterized by chronic wounds, fibrosis and systemic complications. Beremagene geperpavec (B-VEC), a topical HSV1-based gene therapy delivering full-length COL7A1, has shown efficacy in clinical trials; however, real-world data remain limited. This retrospective, descriptive case series reports on three patients with genetically confirmed recessive dystrophic epidermolysis bullosa - two children and one young adult - treated between 2024 and 2026 at two Italian tertiary centres. All patients had extensive chronic skin involvement and received weekly topical B-VEC. Clinical data included wound characteristics, response to therapy, supportive care and adverse events. All patients showed clinically meaningful improvement in target wound healing. One child achieved ~70% reduction in the wound area needing treatment; the second had ~50% with shallower morphology and reduced bleeding. The adult, previously enrolled in the GEM-3 trial, achieved over 60% wound closure after reinitiating B-VEC via Italy's 5% Italian Medicines Agency (AIFA) access programme. No treatment-related adverse events occurred. Adjunctive care included wound hygiene optimization, nutritional and iron support, and pain control. In this small descriptive case series, B-VEC was well tolerated and associated with clinically meaningful improvement in wound healing though outcomes were more variable and, in some cases, less pronounced than those reported in pivotal trials, nevertheless supporting its integration into a comprehensive care model that addresses infection risk, anaemia, nutrition, and wound management.
2026-06-30 | Clinical outcomes of gentamicin therapy in dystrophic Epidermolysis Bullosa: a case-based literature review
Introduction: Epidermolysis bullosa (EB) comprises a group of inherited disorders characterized by skin fragility and blister formation resulting from mutations in proteins essential for dermoepidermal adhesion. Dystrophic EB (DEB), particularly its recessive form (RDEB), is caused by mutations in the COL7A1 gene, leading to defective type VII collagen and impaired anchoring fibrils. Clinically, severe forms are associated with chronic wounds, scarring, pseudosyndactyly, mucosal involvement, and increased risk of cutaneous squamous cell carcinoma. Current therapeutic options remain limited and largely supportive. Gentamicin has emerged as a potential disease-modifying therapy due to its ability to induce translational readthrough of nonsense mutations, restoring partial production of functional collagen VII. This study aims to analyze published cases of EB treated with gentamicin and identify patterns in clinical response and therapeutic outcomes. Methodology: A case-based literature review was conducted, including studies published between 2020 and 2026, retrieved from the PubMed and SciELO databases, in English, Portuguese, and Spanish. Patients with severe generalized dystrophic epidermolysis bullosa treated with gentamicin were included. Extracted variables comprised age, sex, EB subtype, genetic mutation, route of administration (topical or intravenous), treatment duration, methods used to assess response (including immunofluorescence, quality of life scales, and pain scores), collagen VII expression before and after treatment, clinical improvement, adverse effects, and follow-up duration. Data from four studies were compiled into a comparative table to identify trends in therapeutic response and safety outcomes. Discussion: Across the analyzed cases, gentamicin therapy was consistently associated with increased expression of type VII collagen and corresponding clinical improvement, including enhanced wound healing and reduction of mucocutaneous lesions. These findings support its mechanism of action as a readthrough agent that partially restores protein synthesis in patients with nonsense mutations in COL7A1. Both topical and intravenous routes demonstrated therapeutic benefit, although with different clinical profiles. Topical administration was predominantly associated with localized improvement, particularly in oral and cutaneous lesions, reflecting its direct action on treated areas. In contrast, intravenous administration was associated with more systemic effects. Despite these promising findings, variability in treatment response was observed, likely influenced by mutation type, disease severity, and differences in treatment protocols. Additionally, methodological heterogeneity across studies, such as variation in biopsy sites, outcome measures, and duration of therapy, limits direct comparability. Importantly, no significant adverse effects were reported across the included studies, suggesting a favorable short-term safety profile. Some studies also demonstrated maintenance of collagen VII expression after treatment discontinuation, although without evidence of progressive improvement over time. Conclusion: Gentamicin appears to be a promising therapeutic strategy for patients with dystrophic epidermolysis bullosa, particularly those with nonsense mutations in COL7A1. The available evidence demonstrates increased collagen VII expression and associated clinical improvement, regardless of the route of administration. The absence of significant adverse effects supports its short-term safety. However, further large-scale and controlled studies are needed to establish standardized treatment protocols and confirm long-term efficacy.
2026-06-28 | Identification of a long-term surviving human mesenchymal stromal cell subpopulation and implications for recessive dystrophic epidermolysis bullosa treatment.
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin disease caused by loss-of-function pathogenic variants in COL7A1 encoding type VII collagen (C7). Patients with RDEB suffer since birth from skin and mucosal blistering and develop severe local and systemic complications resulting in poor prognosis. Mesenchymal stromal cells (MSCs) have demonstrated their potential to enhance wound healing and reduce skin inflammation in RDEB patients due to their anti-inflammatory properties and capacity to express C7. We aim to optimize in vitro conditioning of human bone marrow-derived MSCs (BM-MSCs) to improve their limited survival following local injection in a murine model. BM-MSCs from healthy human donors were transduced with a lentiviral vector encoding firefly luciferase and mCherry reporter proteins and then subjected to various culture conditions: monolayer on plastic or spheroid culture, either in hypoxia (5% O2) or in normoxia (21% O2). These cells were subsequently injected intradermally (ID) in immunodeficient mice and their survival was assessed by in vivo imaging. BM-MSCs populations were analyzed prior to injection by single-cell RNA sequencing (scRNAseq). Murine skin injected with BM-MSCs were sampled two months post-injection and the surviving subpopulations were characterized by spatial transcriptomic. scRNAseq analysis revealed marked variations between monolayer and spheroid conditions, which were significantly impacted by oxygen level. Although most injected cells gradually died within the first 2 months in all tested conditions, 1% of live bioluminescent cells persisted for 54 up to 61 weeks post-injection. Spatial transcriptomics data analysis demonstrated that all surviving cells, regardless of their in vitro preconditioning, retained the expression of the MSC markers THY1, ENG, and NT5E, shared features with fibroblasts, and exhibited enriched expression in genes related to extracellular matrix and collagen fibril organization, which are key processes in wound healing. Spatial transcriptomic and scRNAseq data integration suggested that surviving BM-MSCs were initially present in the injected population, regardless of their culture condition. Remarkably, none of the in vitro preconditioning strategies appeared to affect their survival capacity or functional properties following local injection. The identification and characterization of a BM-MSC subpopulation capable of long-term survival following ID injection hold promise for the development of improved cell therapy protocols for RDEB.
2026-05-21 | MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.
Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic COL7A1 mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory control remains a major unmet need. While systemic administration of mesenchymal stromal cells (MSC) from various sources has proven safe with transient benefits yet only one recent placebo-controlled study in RDEB. Consistent type VII collagen (C7) deposition is lacking, and therapeutic mechanisms and predictive biomarkers remain undefined. The MesenSistem-EB trial evaluated for the first time the use of haploidentical BM-MSC and extensively explored their anti-inflammatory potential as a monotherapy in RDEB. Phase I/II, single-center, open-label trial, in which nine children with severe RDEB were recruited and eight completed the study after three intravenous infusions of haploidentical BM-MSC (2-3×106 cells/kg) at 21-day intervals. Safety, clinical and patient-reported outcomes, systemic inflammatory mediators and peripheral blood immune profiles were assessed over 12 months. MSC therapy was well-tolerated without serious adverse events. Long-term pruritus, sleep and fatigue were globally reduced. In 7/8 patients at least one key domain significantly improved (disease severity, pruritus, or inflammation) with five classified as good responders. Global median CRP and fibrinogen levels remained stable throughout the study period. Responses correlated with sCD40L and MCP1 dynamics. Flow cytometry revealed altered circulating myeloid and lymphoid compartments at baseline. Post-infusion, immune cell subset changes did not consistently distinguish responders while typically including increased CLA expression on monocytes, partial recovery of memory CD8+ T cells and disappearance of an aberrant granulocyte population, potentially linked to immature myeloid mobilization driven by chronic inflammation. Haploidentical MSC did not consistently confer durable engraftment or sustained C7 deposition. BM-MSC is a safe and potentially effective anti-inflammatory intervention that mitigates the expected escalation of systemic inflammatory markers during a critical phase of RDEB progression. MCP1 and sCD40L modulation, with both potentially serving as predictive biomarkers. MSC appear to exert both shared and patient-specific immunomodulatory effects depending on baseline inflammatory cues. Findings provide insights into individual variability, underlying mechanisms and potential therapeutic responsiveness, supporting their use also as a complementary strategy. ClinicalTrials.gov, identifier NCT04153630.
2026-05-13 | Amniotic Membrane Transplantation Preserves Vision in Pediatric Recessive Dystrophic Epidermolysis Bullosa: Case Series.
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited disorder characterized by extreme epithelial fragility and progressive cicatrization, frequently leading to severe ocular surface disease and early visual impairment. Surgical interventions such as ocular surface reconstruction (OSR) in childhood are often delayed because of anesthetic risks and concerns regarding recurrence. Consequently, the effectiveness of OSR, including amniotic membrane transplantation (AMT), and its impact on visual development remain poorly documented. Methods: We report a case series of two pediatric patients (three eyes) with genetically confirmed RDEB who underwent single-step OSR using AMT. Clinical outcomes, long-term visual acuity, perioperative management, and histopathological findings were evaluated. Results: Ocular manifestations included corneal epithelial damage, symblepharon, and pseudopterygium extending over the cornea. One patient underwent symblepharon lysis, superficial keratectomy, and AMT onto the bare sclera in the right eye at age 4 and in the left eye at age 8, both under intubated general anesthesia. The other patient underwent the same procedure in the right eye at age 6. Best spectacle-corrected visual acuity improved from ≤20/300 to 20/30 in all eyes, and pupillary zone clarity was maintained during the follow-up period (up to 6 years). Histopathology confirmed pseudopterygium with squamous metaplasia, goblet cell loss, and fibrovascular stroma. Safe general anesthesia was achieved through meticulous multidisciplinary perioperative planning involving anesthesiologists, dermatologists, and pediatricians. No systemic complications related to anesthesia or perioperative management were observed. Conclusions: Single-step OSR with on-lay AMT can restore and preserve visual function in pediatric RDEB. Early surgical intervention may prevent profound amblyopia and provide durable ocular surface stability. A multidisciplinary approach enables safe general anesthesia and perioperative management.
2026-08-11 | Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy - a case series.
Recessive dystrophic epidermolysis bullosa is a severe inherited blistering disorder characterized by chronic wounds, fibrosis and systemic complications. Beremagene geperpavec (B-VEC), a topical HSV1-based gene therapy delivering full-length COL7A1, has shown efficacy in clinical trials; however, real-world data remain limited. This retrospective, descriptive case series reports on three patients with genetically confirmed recessive dystrophic epidermolysis bullosa - two children and one young adult - treated between 2024 and 2026 at two Italian tertiary centres. All patients had extensive chronic skin involvement and received weekly topical B-VEC. Clinical data included wound characteristics, response to therapy, supportive care and adverse events. All patients showed clinically meaningful improvement in target wound healing. One child achieved ~70% reduction in the wound area needing treatment; the second had ~50% with shallower morphology and reduced bleeding. The adult, previously enrolled in the GEM-3 trial, achieved over 60% wound closure after reinitiating B-VEC via Italy's 5% Italian Medicines Agency (AIFA) access programme. No treatment-related adverse events occurred. Adjunctive care included wound hygiene optimization, nutritional and iron support, and pain control. In this small descriptive case series, B-VEC was well tolerated and associated with clinically meaningful improvement in wound healing though outcomes were more variable and, in some cases, less pronounced than those reported in pivotal trials, nevertheless supporting its integration into a comprehensive care model that addresses infection risk, anaemia, nutrition, and wound management.
2026-06-30 | Clinical outcomes of gentamicin therapy in dystrophic Epidermolysis Bullosa: a case-based literature review
Introduction: Epidermolysis bullosa (EB) comprises a group of inherited disorders characterized by skin fragility and blister formation resulting from mutations in proteins essential for dermoepidermal adhesion. Dystrophic EB (DEB), particularly its recessive form (RDEB), is caused by mutations in the COL7A1 gene, leading to defective type VII collagen and impaired anchoring fibrils. Clinically, severe forms are associated with chronic wounds, scarring, pseudosyndactyly, mucosal involvement, and increased risk of cutaneous squamous cell carcinoma. Current therapeutic options remain limited and largely supportive. Gentamicin has emerged as a potential disease-modifying therapy due to its ability to induce translational readthrough of nonsense mutations, restoring partial production of functional collagen VII. This study aims to analyze published cases of EB treated with gentamicin and identify patterns in clinical response and therapeutic outcomes. Methodology: A case-based literature review was conducted, including studies published between 2020 and 2026, retrieved from the PubMed and SciELO databases, in English, Portuguese, and Spanish. Patients with severe generalized dystrophic epidermolysis bullosa treated with gentamicin were included. Extracted variables comprised age, sex, EB subtype, genetic mutation, route of administration (topical or intravenous), treatment duration, methods used to assess response (including immunofluorescence, quality of life scales, and pain scores), collagen VII expression before and after treatment, clinical improvement, adverse effects, and follow-up duration. Data from four studies were compiled into a comparative table to identify trends in therapeutic response and safety outcomes. Discussion: Across the analyzed cases, gentamicin therapy was consistently associated with increased expression of type VII collagen and corresponding clinical improvement, including enhanced wound healing and reduction of mucocutaneous lesions. These findings support its mechanism of action as a readthrough agent that partially restores protein synthesis in patients with nonsense mutations in COL7A1. Both topical and intravenous routes demonstrated therapeutic benefit, although with different clinical profiles. Topical administration was predominantly associated with localized improvement, particularly in oral and cutaneous lesions, reflecting its direct action on treated areas. In contrast, intravenous administration was associated with more systemic effects. Despite these promising findings, variability in treatment response was observed, likely influenced by mutation type, disease severity, and differences in treatment protocols. Additionally, methodological heterogeneity across studies, such as variation in biopsy sites, outcome measures, and duration of therapy, limits direct comparability. Importantly, no significant adverse effects were reported across the included studies, suggesting a favorable short-term safety profile. Some studies also demonstrated maintenance of collagen VII expression after treatment discontinuation, although without evidence of progressive improvement over time. Conclusion: Gentamicin appears to be a promising therapeutic strategy for patients with dystrophic epidermolysis bullosa, particularly those with nonsense mutations in COL7A1. The available evidence demonstrates increased collagen VII expression and associated clinical improvement, regardless of the route of administration. The absence of significant adverse effects supports its short-term safety. However, further large-scale and controlled studies are needed to establish standardized treatment protocols and confirm long-term efficacy.
2026-06-28 | Identification of a long-term surviving human mesenchymal stromal cell subpopulation and implications for recessive dystrophic epidermolysis bullosa treatment.
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin disease caused by loss-of-function pathogenic variants in COL7A1 encoding type VII collagen (C7). Patients with RDEB suffer since birth from skin and mucosal blistering and develop severe local and systemic complications resulting in poor prognosis. Mesenchymal stromal cells (MSCs) have demonstrated their potential to enhance wound healing and reduce skin inflammation in RDEB patients due to their anti-inflammatory properties and capacity to express C7. We aim to optimize in vitro conditioning of human bone marrow-derived MSCs (BM-MSCs) to improve their limited survival following local injection in a murine model. BM-MSCs from healthy human donors were transduced with a lentiviral vector encoding firefly luciferase and mCherry reporter proteins and then subjected to various culture conditions: monolayer on plastic or spheroid culture, either in hypoxia (5% O2) or in normoxia (21% O2). These cells were subsequently injected intradermally (ID) in immunodeficient mice and their survival was assessed by in vivo imaging. BM-MSCs populations were analyzed prior to injection by single-cell RNA sequencing (scRNAseq). Murine skin injected with BM-MSCs were sampled two months post-injection and the surviving subpopulations were characterized by spatial transcriptomic. scRNAseq analysis revealed marked variations between monolayer and spheroid conditions, which were significantly impacted by oxygen level. Although most injected cells gradually died within the first 2 months in all tested conditions, 1% of live bioluminescent cells persisted for 54 up to 61 weeks post-injection. Spatial transcriptomics data analysis demonstrated that all surviving cells, regardless of their in vitro preconditioning, retained the expression of the MSC markers THY1, ENG, and NT5E, shared features with fibroblasts, and exhibited enriched expression in genes related to extracellular matrix and collagen fibril organization, which are key processes in wound healing. Spatial transcriptomic and scRNAseq data integration suggested that surviving BM-MSCs were initially present in the injected population, regardless of their culture condition. Remarkably, none of the in vitro preconditioning strategies appeared to affect their survival capacity or functional properties following local injection. The identification and characterization of a BM-MSC subpopulation capable of long-term survival following ID injection hold promise for the development of improved cell therapy protocols for RDEB.
2026-05-21 | MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.
Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic COL7A1 mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory control remains a major unmet need. While systemic administration of mesenchymal stromal cells (MSC) from various sources has proven safe with transient benefits yet only one recent placebo-controlled study in RDEB. Consistent type VII collagen (C7) deposition is lacking, and therapeutic mechanisms and predictive biomarkers remain undefined. The MesenSistem-EB trial evaluated for the first time the use of haploidentical BM-MSC and extensively explored their anti-inflammatory potential as a monotherapy in RDEB. Phase I/II, single-center, open-label trial, in which nine children with severe RDEB were recruited and eight completed the study after three intravenous infusions of haploidentical BM-MSC (2-3×106 cells/kg) at 21-day intervals. Safety, clinical and patient-reported outcomes, systemic inflammatory mediators and peripheral blood immune profiles were assessed over 12 months. MSC therapy was well-tolerated without serious adverse events. Long-term pruritus, sleep and fatigue were globally reduced. In 7/8 patients at least one key domain significantly improved (disease severity, pruritus, or inflammation) with five classified as good responders. Global median CRP and fibrinogen levels remained stable throughout the study period. Responses correlated with sCD40L and MCP1 dynamics. Flow cytometry revealed altered circulating myeloid and lymphoid compartments at baseline. Post-infusion, immune cell subset changes did not consistently distinguish responders while typically including increased CLA expression on monocytes, partial recovery of memory CD8+ T cells and disappearance of an aberrant granulocyte population, potentially linked to immature myeloid mobilization driven by chronic inflammation. Haploidentical MSC did not consistently confer durable engraftment or sustained C7 deposition. BM-MSC is a safe and potentially effective anti-inflammatory intervention that mitigates the expected escalation of systemic inflammatory markers during a critical phase of RDEB progression. MCP1 and sCD40L modulation, with both potentially serving as predictive biomarkers. MSC appear to exert both shared and patient-specific immunomodulatory effects depending on baseline inflammatory cues. Findings provide insights into individual variability, underlying mechanisms and potential therapeutic responsiveness, supporting their use also as a complementary strategy. ClinicalTrials.gov, identifier NCT04153630.
2026-05-13 | Amniotic Membrane Transplantation Preserves Vision in Pediatric Recessive Dystrophic Epidermolysis Bullosa: Case Series.
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited disorder characterized by extreme epithelial fragility and progressive cicatrization, frequently leading to severe ocular surface disease and early visual impairment. Surgical interventions such as ocular surface reconstruction (OSR) in childhood are often delayed because of anesthetic risks and concerns regarding recurrence. Consequently, the effectiveness of OSR, including amniotic membrane transplantation (AMT), and its impact on visual development remain poorly documented. Methods: We report a case series of two pediatric patients (three eyes) with genetically confirmed RDEB who underwent single-step OSR using AMT. Clinical outcomes, long-term visual acuity, perioperative management, and histopathological findings were evaluated. Results: Ocular manifestations included corneal epithelial damage, symblepharon, and pseudopterygium extending over the cornea. One patient underwent symblepharon lysis, superficial keratectomy, and AMT onto the bare sclera in the right eye at age 4 and in the left eye at age 8, both under intubated general anesthesia. The other patient underwent the same procedure in the right eye at age 6. Best spectacle-corrected visual acuity improved from ≤20/300 to 20/30 in all eyes, and pupillary zone clarity was maintained during the follow-up period (up to 6 years). Histopathology confirmed pseudopterygium with squamous metaplasia, goblet cell loss, and fibrovascular stroma. Safe general anesthesia was achieved through meticulous multidisciplinary perioperative planning involving anesthesiologists, dermatologists, and pediatricians. No systemic complications related to anesthesia or perioperative management were observed. Conclusions: Single-step OSR with on-lay AMT can restore and preserve visual function in pediatric RDEB. Early surgical intervention may prevent profound amblyopia and provide durable ocular surface stability. A multidisciplinary approach enables safe general anesthesia and perioperative management.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form.
1 orphan drug designation for Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Angiotensin (1-7) | peptides | FDA | 2016-09-01 | — | Constant Therapeutics LLC |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.